The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.
| Level | Code | Title | |
|---|---|---|---|
| 1 | V | Various | |
| 2 | V03 | All other therapeutic products | |
| 3 | V03A | All other therapeutic products | |
| 4 | V03AF | Detoxifying agents for antineoplastic treatment | |
| 5 | V03AF03 | Calcium folinate |
The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. The DDD is a unit of measurement and does not necessarily reflect the recommended or Prescribed Daily Dose. Therapeutic doses for individual patients and patient groups will often differ from the DDD as they will be based on individual characteristics (such as age, weight, ethnic differences, type and severity of disease) and pharmacokinetic considerations.
| Route | Amount |
|---|---|
| ORAL - Oral | 60 mg |
| PAREN - Parenteral | 60 mg |
| Active Ingredient | Description | |
|---|---|---|
| Calcium folinate |
Calcium folinate is an active metabolite of folinic acid and essential coenzyme for nucleic acid synthesis in cytotoxic therapy. Calcium folinate is frequently used to diminish the toxicity and counteract the action of folate antagonists, such as methotrexate. |
| Title | Information Source | Document Type | |
|---|---|---|---|
| CALCIUM FOLINATE Solution for injection / infusion | Medicines & Healthcare Products Regulatory Agency (GB) | MPI, EU: SmPC | |
| CALCIUM FOLINATE Tablet | Medicines & Healthcare Products Regulatory Agency (GB) | MPI, EU: SmPC | |
| REFOLINON Tablet | Medicines & Healthcare Products Regulatory Agency (GB) | MPI, EU: SmPC |
Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide.
